Keytruda, also known as pembrolizumab, is a cancer medication developed by Merck & Co. The US Food and Drug Administration… https://www.Drugchatter.com/chat/26764/what’s-the-exact-date-of-keytruda’s-first-fda-approval/

Keytruda, also known as pembrolizumab, is a cancer medication developed by Merck & Co. The US Food and Drug Administration… https://www.Drugchatter.com/chat/26764/what’s-the-exact-date-of-keytruda’s-first-fda-approval/

Keytruda, also known as pembrolizumab, is a cancer medication developed by Merck & Co. The US Food and Drug Administration… https://www.Drugchatter.com/chat/26764/what’s-the-exact-date-of-keytruda’s-first-fda-approval/

Keytruda, also known as pembrolizumab, is a cancer medication developed by Merck & Co. The US Food and Drug Administration… https://www.Drugchatter.com/chat/26764/what’s-the-exact-date-of-keytruda’s-first-fda-approval/

Small molecules vs. biologics: the “same” IP fight—different playbooks for generics and biosimilars
Most IP teams treat drug patents as if the strategy is transferable across modalities. It isn’t.
A small-molecule portfolio and a biologics portfolio ma…

Biopharma vendors don’t lose deals because they’re “too late.” They lose because they’re invisible—until it’s too late.
In EU markets, the tender cycle around loss of exclusivity (LoE) is brutal: once the patent clock runs out, procurement teams move f…

Pharma doesn’t always need a new molecule to make billions. It needs a new story.
For years, the industry’s “innovation” narrative has been anchored to breakthrough compounds—new targets, new mechanisms, new patents. But a quieter, more lucrative playb…

Biopharma is entering a new kind of “cliff”—not just patent expiration, but the operational scramble that follows it.
When loss of exclusivity hits, the market doesn’t simply get cheaper. It gets faster. Generics arrive with aggressive pricing, payers …

One-shot strategy: how to pick the right drug patent for maximum extension value
Most pharma teams treat patent term extension like an administrative afterthought—something to file, track, and hope works out.
But in a world where timelines are compress…

Drug patent litigation isn’t just about what’s claimed—it’s about what’s designed around.
In the pharmaceutical world, “design around” sounds like a strategy. In practice, it’s a discipline: a way to translate patent language into formulation decisio…